Antibody panels for immune checkpoints

Discover our range of hand-picked antibody panels to key immuno-oncology targets designed to save you time and provide you with easy access to the best selection of clones on the market. Each panel contains a selection of monoclonal antibodies that detect the same protein to increase your chances of finding a compatible clone for your assay with just one purchase.

Product code Panel name

ab252195 GITR

ab252193 LAG-3

ab252192 PD1

ab239749 PD-L1 Component product code Size Component name Tested applications Species reactivity

ab223841 20 µl Anti-GITR antibody [EPR20566] ICC/IF, IHC-P, WB Hu

ab237714 20 µl Anti-GITR antibody [CAL8] Flow Cyt, IHC-P Hu

ab237713 20 µl Anti-GITR antibody [CAL52] Flow Cyt, ICC/IF, IHC-P, IP Hu

ab209236 20 µl Anti-LAG-3 antibody [EPR20261]

Flow Cyt, ICC/IF, IHC-P, IP, WB Hu ab180187 20 µl Anti-LAG-3 antibody [EPR4392(2)] - C-terminal IHC-P ab227706 20 µl Anti-LAG-3 antibody [SP346] - C-terminal IHC-P Hu

Hu

ab237720 20 µl Anti-LAG-3 antibody [CAL77] Flow Cyt, IHC-P Hu,Ms

ab237718 20 µl Anti-LAG-3 antibody [CAL25] Flow Cyt, IHC-P, IP, WB Hu

ab237719 20 µl Anti-LAG-3 antibody [CAL26] IHC-P Hu

ab237728 20 µl Anti-PD1 antibody [CAL20] ICC/IF, IHC-P, WB Hu

ab137132 20 µl Anti-PD1 antibody [EPR4877(2)] IHC-P Hu

ab227681 20 µl Anti-PD1 antibody [SP269] Flow Cyt, IHC-P Hu

ab52587 20 µl Anti-PD1 antibody [NAT105] Flow Cyt, ICC/IF, IHC-P, IHC-Fr, IP, WB Hu ab216352 20 µl Anti-PD1 antibody [NAT105EPR21106] - Chimeric Flow Cyt, IHC-P, IP, WB Hu

ab228415 1 x 10 µl Anti-PD-L1 antibody [73-10] Flow Cyt, ICC/IF, IHC-P, IP, WB Hu ab205921 1 x 10 µl Anti-PD-L1 antibody [28-8] Flow Cyt, ICC/IF, IHC-P, WB Hu ab228462 1 x 25 µl Anti-PD-L1 antibody [SP142] - C-terminal ICC/IF, IHC-P ChHm, Hu

ab237726 1 x 10 µl Anti-PD-L1 antibody [CAL10] ELISA, ICC/IF, IHC-P, IP, WB Hu

ab269812 PD-L1 / PD1 Multiplex IHC-IF

ab252191 TIM 3 Component product code Size Component name Tested applications ab16669 1 x 50 µl Anti-CD3 antibody [SP7] Flow Cyt, IHC-P, mIHC, WB Hu,Ms, Rat

ab7753 1 x 50 µg Anti-pan Cytokeratin antibody [C-11] ab192847 1 x 50 µl Recombinant Anti-CD68 antibody [SP251] ab16667 1 x 50 µl Recombinant Anti-Ki67 antibody [SP6] ab237728 1 x 50 µl Recombinant Anti-PD1 antibody [CAL20] ab237726 1 x 50 µl Recombinant Anti-PD-L1 antibody [CAL10] ab241332 20 µl Anti-TIM 3 antibody [EPR22241] Flow Cyt, IHC-P, mIHC, WB Flow Cyt, IHC-P, mIHC Cm, Goat, Hu,Rat

Hu

Flow Cyt, ICC, IHC-P, mIHC, WB Hu,Ms, Rat ICC/IF,I HC-P, mIHC, WB Hu

ELISA, ICC/IF, IHC-P, IP, mIHC, WB Hu

IHC-P, IP, WB Hu,Ms

ab246851 20 µl Anti-TIM 3 antibody [CAL68] IHC-P Hu

ab252533 20 µl Anti-TIM 3 antibody [BLR033F] ICC, IHC-P, WB Hu

ChHm: Chinese Hamster; Cm: Common marmoset; Goat: Goat; Hu: Human; Ms: Mouse; Rat: Rat. ELISA: ELISA; Flow Cyt: Flow Cytometry; ICC: Immunocytochemistry; ICC/IF: Immunocytochemistry / Immunofluorescence; IF: Immunofluorescence; IHC: Immunofluorescence; IHC-Fr: Immunohistochemistry (Frozen sections); IHC-P: Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections); IP: Immunoprecipitation; mIHC: Fluorescent multiplex immunohistochemistry; WB: Western blot

1. Sanmamed, M. F. & Chen, L. A Paradigm Shift in Cancer Immunotherapy: From

Enhancement to Normalization. Cell 175, 313-326, doi:10.1016/j.cell.2018.09.035 (2018).

2. Xin Yu, J. et al. Trends in clinical development for PD-1/PD-L1 inhibitors. Nature reviews. Drug discovery 19, 163-164, doi:10.1038/d41573-019-00182-w (2020).

3. Cancer Research website, <www.cancerresearch.org/scientists/immuno-oncologylandscape/pd-1-pd-l1-landscape>

4. Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature medicine 8, 793-800, doi:10.1038/nm730 (2002).

5. Petroff, M. G., Chen, L., Phillips, T. A. & Hunt, J. S. B7 family molecules: novel immunomodulators at the maternal-fetal interface. Placenta 23 Suppl A, S95-101, doi:10.1053/plac.2002.0813 (2002).

6. Chen, L. & Han, X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. The

Journal of clinical investigation 125, 3384-3391, doi:10.1172/JCI80011 (2015).

7. Francisco, L. M. et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. The Journal of experimental medicine 206, 3015-3029, doi:10.1084/jem.20090847 (2009).

8. Amarnath, S. et al. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Science translational medicine 3, 111ra120, doi:10.1126/scitranslmed.3003130 (2011).

9. Dong, H., Zhu, G., Tamada, K. & Chen, L. B7-H1, a third member of the B7 family, costimulates T-cell proliferation and interleukin-10 secretion. Nature medicine 5, 1365-1369, doi:10.1038/70932 (1999).

10. Selenko-Gebauer, N. et al. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. Journal of immunology 170, 3637-3644, doi:10.4049/jimmunol.170.7.3637 (2003).

11. Tsushima, F. et al. Interaction between B7-H1 and PD-1 determines initiation and reversal of

T-cell anergy. Blood 110, 180-185, doi:10.1182/blood-2006-11-060087 (2007).

12. Goldberg, M. V. et al. Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood 110, 186-192, doi:10.1182/blood-2006-12-062422 (2007).

13. Yao, S. et al. PD-1 on dendritic cells impedes innate immunity against bacterial infection.

Blood 113, 5811-5818, doi:10.1182/blood-2009-02-203141 (2009).

14. Azuma, T. et al. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111, 3635-3643, doi:10.1182/blood-2007-11-123141 (2008).

15. Sznol, M. & Chen, L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response. Clinical cancer research : an official journal of the

American Association for Cancer Research 19, 5542, doi:10.1158/1078-0432.CCR-13-2234 (2013).

16. Taube, J. M. et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Science translational medicine 4, 127ra137, doi:10.1126/scitranslmed.3003689 (2012).

17. Zhang, Y. & Chen, L. Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy. JAMA oncology 2, 1403-1404, doi:10.1001/jamaoncol.2016.2450 (2016).

18. Horn, L. et al. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced

Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label,

Phase III Trials (CheckMate 017 and CheckMate 057). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 35, 3924-3933, doi:10.1200/

JCO.2017.74.3062 (2017).

19. Wu, Y. L. et al. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population

With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical

Trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 14, 867-875, doi:10.1016/j.jtho.2019.01.006 (2019).

20. Agilent website <https://www.agilent.com/en/product/pharmdx/pd-l1-ihc-28-8-pharmdx/ pd-l1-ihc-28-8-pharmdx-for-autostainer-link-48-76917>

21. PD-L1 检测试剂盒（免疫组织化学法）体外诊断试剂产品注册技术审评报告. 22. NMPA website, <www.nmpa.gov.cn/WS04/CL2042>

23. FDA website, <www.fda.gov/medical-devices/vitro-diagnostics>

24. Hirsch, F. R. et al. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 12, 208-222, doi:10.1016/j.jtho.2016.11.2228 (2017).

25. Tsao, M. S. et al. PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical

Samples: Results of Blueprint Phase 2 Project. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 13, 1302-1311, doi:10.1016/j.jtho.2018.05.013 (2018).